RT Journal Article
SR Electronic
T1 Neonatal Antiphospholipid Syndrome
JF NeoReviews
JO NeoReviews
FD American Academy of Pediatrics
SP e169
OP e176
DO 10.1542/neo.15-5-e169
VO 15
IS 5
A1 Magalhães, Claudia Saad
A1 Suppo de Souza Rugolo, Ligia Maria
A1 Trindade, Cleide Enoir Petean
YR 2014
UL http://neoreviews.aappublications.org/content/15/5/e169.abstract
AB Abbreviations:AID, autoimmune diseasesAPS, antiphospholipid antibody syndromeaPLs, antiphospholipid antibodiesaCLs, anticardiolipin antibodiesCAPS, catastrophic antiphospholipid antibody syndromeGP-I, anti-β-2 glycoprotein I antibodiesHLA, histocompatibility leukocyte antigenIg, immunoglobulinLA, lupus anticoagulantSLE, systemic lupus erythematosusAntiphospholipid antibody syndrome (APS) during pregnancy may result in pregnancy morbidity and passive transfer of antibodies to the fetus, resulting in an increased risk of prematurity, intrauterine growth restriction, thrombocytopenia, and developmental delay. Antiphospholipid antibodies may have an impact on neurodevelopment during fetal life. Although rare, persistence of these antibodies in the neonate may lead to thromboembolism, particularly if there is a concurrent infection and/or inherited thrombophilic disorders. Affected pregnant women need to be identified early during gestation so that they can have close monitoring of the placental circulation, fetal growth and development, and testing of serum antiphospholipid antibody levels. Neonates born to mothers with antiphospholipid antibody syndrome should have close neurodevelopment follow-up.